Raymond B. Nagle

University of Arizona — United States

Medicine · Health Sciences

55h-index12.0kcitations263works1.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(70), Cell Adhesion Molecules Research(69), Protease and Inhibitor Mechanisms(28), Prostate Cancer Diagnosis and Treatment(23), Molecular Biology Techniques and Applications(20)

Publications263 total

Intermediate risk prostate tumors contain lethal subtypes
Frontiers in Urology·2025· 1 citedOpen Access
Biophysical phenotype mixtures reveal advantages for tumor muscle invasion in vivo
Biophysical Journal·2023· 3 citedOpen Access
Abstract B001: Heterogeneity of cancer network biophysical phenotypes is required for tumor muscle invasion <i>in vivo</i>
Cancer Research·2023
Figure S2 from Novel Regulation of Integrin Trafficking by Rab11-FIP5 in Aggressive Prostate Cancer
2023Open Access
Supplementary Methods, Tables 1 - 3, Figures 1 - 2 from Does Mutated &lt;i&gt;K-RAS&lt;/i&gt; Oncogene Attenuate the Effect of Sulindac in Colon Cancer Chemoprevention?
2023Open Access
Figure S4 from Novel Regulation of Integrin Trafficking by Rab11-FIP5 in Aggressive Prostate Cancer
2023Open Access
Data from Novel Regulation of Integrin Trafficking by Rab11-FIP5 in Aggressive Prostate Cancer
2023Open Access
Data from Novel Regulation of Integrin Trafficking by Rab11-FIP5 in Aggressive Prostate Cancer
2023Open Access
Figure S1 from Novel Regulation of Integrin Trafficking by Rab11-FIP5 in Aggressive Prostate Cancer
2023Open Access
Figure S3 from Novel Regulation of Integrin Trafficking by Rab11-FIP5 in Aggressive Prostate Cancer
2023Open Access
Data from Does Mutated &lt;i&gt;K-RAS&lt;/i&gt; Oncogene Attenuate the Effect of Sulindac in Colon Cancer Chemoprevention?
2023Open Access
Figure S3 from Novel Regulation of Integrin Trafficking by Rab11-FIP5 in Aggressive Prostate Cancer
2023Open Access
Figure S4 from Novel Regulation of Integrin Trafficking by Rab11-FIP5 in Aggressive Prostate Cancer
2023Open Access
Data from Does Mutated &lt;i&gt;K-RAS&lt;/i&gt; Oncogene Attenuate the Effect of Sulindac in Colon Cancer Chemoprevention?
2023Open Access
Figure S2 from Novel Regulation of Integrin Trafficking by Rab11-FIP5 in Aggressive Prostate Cancer
2023Open Access
Figure S1 from Novel Regulation of Integrin Trafficking by Rab11-FIP5 in Aggressive Prostate Cancer
2023Open Access
Supplementary Methods, Tables 1 - 3, Figures 1 - 2 from Does Mutated &lt;i&gt;K-RAS&lt;/i&gt; Oncogene Attenuate the Effect of Sulindac in Colon Cancer Chemoprevention?
2023Open Access
Supplementary Figure 4 from Gene Editing of α6 Integrin Inhibits Muscle Invasive Networks and Increases Cell–Cell Biophysical Properties in Prostate Cancer
2023Open Access
Supplementary Figure 1 from Gene Editing of α6 Integrin Inhibits Muscle Invasive Networks and Increases Cell–Cell Biophysical Properties in Prostate Cancer
2023Open Access
Data from Gene Editing of α6 Integrin Inhibits Muscle Invasive Networks and Increases Cell–Cell Biophysical Properties in Prostate Cancer
2023Open Access
page 1 of 14Next →

Frequent Co-authors

Anne E. Cress(10), David J. Bearss(5), Michael K. Brawer(5), Bruce L. Dalkin(4), Virginia A. Clark(4), Frederick R. Ahmann(4), Haiyong Han(3), Daniel D. Von Hoff(3), Katherine Scott(3), D.C. von Bredow(3), Kathy McDaniel(3), Isis C. Sroka(3), Carolyn C. Compton(2), L P Fielding(2), Lawrence J. Burgart(2), Barbara A. Conley(2), Harry S. Cooper(2), Stanley R. Hamilton(2), Donald E. Henson(2), R. V. P. Hutter(2)